Search Results

Cost-effectiveness analysis of CTZ/TAZ for the treatment of ventilated hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in Japan

• Authors : Risako Takaya; Nobuyoshi Mori; Eiko Saito

Subjects: Ceftolozane/tazobactam; Meropenem; Ventilated-hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia

• Source: BMC Health Services Research, Vol 24, Iss 1, Pp 1-11 (2024)

Record details

Cost Effectiveness of Ceftolozane/Tazobactam Compared with Meropenem for the Treatment of Patients with Ventilated Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia.

• Authors : Naik, Jaesh¹ (AUTHOR); Puzniak, Laura² (AUTHOR); Critchlow, Simone¹ (AUTHOR)

• Source: Infectious Diseases & Therapy. Jun2021, Vol. 10 Issue 2, p939-954. 16p.

Record details

Cost-effectiveness of ceftazidime/avibactam plus metronidazole versus meropenem as first-line empiric therapy for the treatment of complicated intra-abdominal infections: A study based on the in-vitro surveillance data in China

• Authors : Xiaoping Shi; Jie Fu; Xiaoyu Li

Subjects: Cost-effectiveness analysis; Ceftazidime/avibactam; Meropenem

• Source: Journal of Infection and Public Health, Vol 16, Iss 3, Pp 361-367 (2023)

Record details

Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI).

• Authors : Kongnakorn T; Evidera, The Ark, 201 Talgarth Road, Hammersmith, London W6 8BJ UK.; Eckmann C

Subjects: Cost-Benefit Analysis*; Anti-Bacterial Agents/Anti-Bacterial Agents/Anti-Bacterial Agents/*therapeutic use ; Azabicyclo Compounds/Azabicyclo Compounds/Azabicyclo Compounds/*therapeutic use

• Source: Antimicrobial resistance and infection control [Antimicrob Resist Infect Control] 2019 Dec 21; Vol. 8, pp. 204. Date of Electronic Publication: 2019 Dec 21 (Print Publication: Publisher: BioMed Central Country of Publication: England NLM ID: 101585411 Publication Model: eCollection Cited Medium: Internet ISSN: 2047-2994

Record details

Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI)

• Authors : Thitima Kongnakorn; Christian Eckmann; Matteo Bassetti

Subjects: Economic model; Cost-effectiveness analysis; Ceftazidime-avibactam plus metronidazole

• Source: Antimicrobial Resistance and Infection Control, Vol 8, Iss 1, Pp 1-15 (2019)

Record details

Cost-Effectiveness Analysis of Varenicline Versus Currently Funded Smoking Cessation Strategies in Brazil

• Authors : Brayan V. Seixas; Renata Leborato Guerra; Rita de Cássia Ribeiro de Albuquerque

Subjects: medicine.medical_specialty; Cost effectiveness; Transdermal patch

• Source: Value in Health Regional Issues. 27:25-31

Record details

Cost-Utility Analysis of Dapagliflozin Compared to Sulfonylureas for Type 2 Diabetes as Second-Line Treatment in Indian Healthcare Payer’s Perspective

• Authors : Thunyarat Anothaisintawee; Bhavani Shankara Bagepally; Ammarin Thakkinstian

Subjects: medicine.medical_specialty; Cost effectiveness; Economics, Econometrics and Finance (miscellaneous)

• Source: ClinicoEconomics and Outcomes Research: CEORBASE-Bielefeld Academic Search Engine

Record details

Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia–Pacific region

• Authors : Huang Tz Ou; Fang Hsiu Kuo; Hsin Ju Tang

Subjects: Male; Time Factors; Cost effectiveness

• Source: Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-10 (2021)Cardiovascular Diabetology

Record details

Cost-effectiveness of the regimen proposed by the International Consortium on Acute Promyelocytic Leukemia for the treatment of newly diagnosed patients with Acute Promyelocytic Leukemia

• Authors : María del Pilar Ortíz-Vilchis; Roberta Demichelis-Gómez; María José Díaz-Huízar

Subjects: Acute promyelocytic leukemia; medicine.medical_specialty; Cost effectiveness

• Source: Hematology, Transfusion and Cell Therapy, Volume: 43, Issue: 4, Pages: 476-481, Published: 29 NOV 2021Hematology, Transfusion and Cell TherapyHematology, Transfusion and Cell Therapy, Vol

Record details

The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes: a Health Economic Analysis in Sweden

• Authors : Ohad Cohen; Johan Jendle; Samuel J. P. Malkin

Subjects: Sweden; Type 1 diabetes; medicine.medical_specialty

• Source: Diabetes Therapy

Record details